Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBITDA: 2020-2025

Historic EBITDA for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $2.6 million.

  • Mirum Pharmaceuticals' EBITDA rose 120.52% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.8 million, marking a year-over-year increase of 56.45%. This contributed to the annual value of -$87.6 million for FY2024, which is 19.74% up from last year.
  • Mirum Pharmaceuticals' EBITDA amounted to $2.6 million in Q3 2025, which was up 152.17% from -$5.0 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' EBITDA registered a high of $2.6 million during Q3 2025, and its lowest value of -$47.6 million during Q1 2021.
  • Moreover, its 3-year median value for EBITDA was -$24.2 million (2024), whereas its average is -$19.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 116.11% in 2021, then surged by 120.52% in 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' EBITDA (Quarterly) stood at -$45.6 million in 2021, then grew by 25.04% to -$34.2 million in 2022, then increased by 4.61% to -$32.6 million in 2023, then grew by 25.67% to -$24.2 million in 2024, then skyrocketed by 120.52% to $2.6 million in 2025.
  • Its EBITDA stands at $2.6 million for Q3 2025, versus -$5.0 million for Q2 2025 and -$15.2 million for Q1 2025.